PIQ 2.79% 87.0¢ proteomics international laboratories ltd

Ann: Appendix 4C - June 2019 Quarterly Report, page-2

  1. Eqz
    3,304 Posts.
    lightbulb Created with Sketch. 1078

    Pros:
    - Richard met with tier 1 diagnostics groups in the US for the US roll-out
    - News due in 'the coming weeks' around Mexico and Spain roll out
    - Janseen collaboration going as planned, reiterating the potential use of PD every time Gliflozin is prescribed.
    - FY19 receipts were $1.7M, more than double PY
    - Upcoming $1.1m in R&D rebate to further strength cash position which is currently at $1.5M

    Cons:
    - Endometrosis POC delayed due to mass spectrometry machine failure
    - Giardia POC now in a second POC stage? didnt' know 2 POC's were required..
    - Dominican Republic royalties either not included or was minuscule
    - Quarterly receipts only $245k

    Overall pretty good just a dam shame we are taking so long to commercialize PromarkerD considering it was ready nearly 2 years ago.
    One can dream but imagine what this means for us if we partner with a tier1 diagnostics group in the U.S and the Jannsen collaboration goes according to plan? Good luck guys and look forward to every one else thoughts on the quarterly.




 
watchlist Created with Sketch. Add PIQ (ASX) to my watchlist
(20min delay)
Last
87.0¢
Change
-0.025(2.79%)
Mkt cap ! $113.8M
Open High Low Value Volume
89.5¢ 90.0¢ 86.0¢ $271.4K 310.0K

Buyers (Bids)

No. Vol. Price($)
1 300 86.5¢
 

Sellers (Offers)

Price($) Vol. No.
87.0¢ 3277 2
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
87.0¢
  Change
-0.025 ( 3.33 %)
Open High Low Volume
89.5¢ 89.5¢ 86.0¢ 54719
Last updated 15.56pm 14/06/2024 ?
PIQ (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.